Download a copy of this press release here.

Diepenbeek, Belgium and Roden, The Netherlands, March 13, 2026 – Cannovex and PureIMS have entered into a strategic partnership to develop innovative pharmaceutical cannabinoid products. The collaboration combines Cannovex’s proprietary cannabinoid formulations with PureIMS’s patented Cyclops® dry powder inhaler (DPI). Under the terms of the agreement, Cannovex holds exclusive rights to develop pharmaceutical cannabinoid products using the Cyclops® device for a range of active ingredients and indications. Phase I clinical trials are slated to begin in 2027.

Cannovex is built on the conviction that cannabinoids should be developed as rigorous pharmaceutical products. This means adhering to strict scientific standards, pharmaceutical-grade quality, and disciplined regulatory pathways—values fully shared by PureIMS. This partnership marks a shift toward pharmaceutical-grade development standards, including optimized formulations, controlled dosing, and well-defined regulatory pathways.

The Cyclops® inhaler was selected for its ability to deliver precise and reproducible doses of high-load dry powder formulations. This unique capability is particularly important for systemic therapies requiring consistent pharmacokinetic exposure and reliable clinical performance.

Steven Peters, CEO of Cannovex, commented: “With growing scientific evidence supporting the therapeutic potential of cannabinoids, inhalation offers a patient-friendly and highly effective delivery route. Our formulations are specifically designed for the Cyclops® platform to enable consistent systemic exposure across a range of potential therapeutic applications. This partnership provides a strong technological foundation for reproducible dosing, and scalable pharmaceutical-grade manufacturing.”

Jaap Wieling, CEO of PureIMS, added: “This collaboration is a significant milestone for PureIMS and validates the versatility of our Cyclops® platform. Cannovex’ commitment to rigorous science and pharmaceutical quality aligns perfectly with our own standards. By moving away from the inconsistent approaches of the past, we are ensuring that patients receive the maximum therapeutic benefit from these innovative products.”

About Cannovex
Cannovex is a biotechnology company developing pharmaceutical-grade cannabinoid medicines designed to meet the standards of modern drug development. The company focuses on advancing rigorously engineered formulations combined with precision pulmonary delivery to enable rapid and reproducible systemic exposure.

By integrating cannabinoid pharmacology with optimized inhalation technologies, Cannovex aims to unlock the therapeutic potential of cannabinoids within a disciplined clinical and regulatory framework.

Cannovex is currently preparing to advance its inhaled cannabinoid programs toward clinical development and recently launched a new corporate website outlining its scientific rationale, development strategy, and long-term vision.

For more information, please visit www.cannovex.com

About PureIMS B.V.
PureIMS is a Dutch clinical-stage pharmaceutical company based in Roden, specialized in developing and commercializing innovative inhaled therapies for respiratory and systemic diseases. The company utilizes its proprietary Cyclops® platform, a patented, patient-centric dry powder inhaler (DPI) designed for the rapid and effective delivery of high-dose medications to the deep lungs.
In addition to its co-development partnerships, PureIMS maintains an internal pipeline in advanced clinical stages, some of which with orphan designation and/or on hybrid / 505(b)(2) pathways.

For more information, please visit www.pureims.com

 For further inquiries, please contact:

SHARE THIS POST